21 Jun 2013
The US Food and Drug Administration has granted "breakthrough" designation to Novartis' experimental synthetic relaxin drug (Serelaxin) in acute heart failure. Breakthrough status is designed to expediate the development of drugs for serious or life-threatening conditions, including fast-tracking through the approval process and intensive FDA guidance on an efficient drug development program.
Call for nominations for Awards Committee Chair
30 Oct 2024
James M Tanner Award - 2025 nominations open
30 Oct 2024
Would you like to host the BSPED annual meeting?
21 Oct 2024